Methotrexate and immunogenicity of vaccines in patients with rheumatic diseases
Currently, methotrexate (MT) remains one of the immunosuppressive drugs most commonly used in rheumatology. However, its effect on the immunogenicity of vaccines has until recently been studied only to a limited extent, which has led to the lack of clear recommendations for the use of MT during vacc...
Saved in:
| Main Authors: | В. S. Belov, N. V. Muravyeva, Е. L. Nasonov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2024-04-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3550 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Vaccination for rheumatic diseases: Current issues (based on ACR guidelines)
by: B. S. Belov, et al.
Published: (2023-04-01) -
Vaccinoprophylaxis of infections and activity of immuno-inflammatory rheumatic diseases: pro et contra
by: B. S. Belov, et al.
Published: (2024-04-01) -
The use of the combined vector vaccine GamCOVID-Vac (Sputnik V) in patients with immuno-inflammatory rheumatic diseases: safety issues-news
by: A. N. Kulikov, et al.
Published: (2023-06-01) -
Frequency and course of COVID-19 in patients with rheumatic diseases (according to the data of V.A. Nasonova Research Institute of Rheumatology)
by: A. N. Kulikov, et al.
Published: (2023-10-01) -
Unilateral Laterothoracic Exanthem in an Adult Following Recombinant Zoster Vaccination
by: Xinjin Liu, et al.
Published: (2025-07-01)